| Name | Title | Contact Details |
|---|
Cellanyx has developed proprietary live tumor cell phenotypic biomarker tests to improve cancer risk-stratification and allow informed clinical decision making. The Companys unique approach provides quantitative and actionable information based on analysis of thousands of live tumor cells. The Companys tests employ a microfluidic platform combined with machine vision and machine learning approaches to analyze phenotypic morphological, biochemical and biophysical markers. Cellanyx has demonstrated initial clinical proof-of-concept with its lead phenotypic test in prostate cancer. The initial clinical proof-of-concept study was conducted to demonstrate improved risk stratification in men with low and intermediate Gleason grade (6 and 7) disease and reduce the number of repeat biopsies. Furthermore, analysis of field samples (away from the suspicious core) demonstrated the potential value of Cellanyx phenotypic test as it was able to analyze the tumor microenvironment conditions and predict expected adverse pathology from samples that were not taken from the suspicious core. These new findings from the Cellanyx prostate test are transformative as it will reduce the errors in diagnosing cancers early due to sampling heterogeneity of prostate biopsies.
Marcus Institute is a Atlanta, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Biotab Nutraceuticals is a Monrovia, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Academy of Psychosematic Medicine is a Bethesda, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Austin-based Superior HealthPlan (Superior) is a managed care company that employs more than 3,400 people across nine Texas offices. Superior is a wholly-owned subsidiary of Centene Corporation, a diversified, multi-national healthcare enterprise. Superior is licensed by the Texas Department of Insurance and is a Qualified Health Plan issuer in the Texas Health Insurance Marketplace.